Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results

Combining Eli Lilly's Taltz with Zepbound could enhance psoriasis, metabolic benefits

Lilly’s TOGETHER-PsO trial: Taltz + Zepbound may boost psoriasis and metabolic biomarkers in obese/overweight patients. Read more here.

Lilly Trial Links Taltz-Zepbound Combination to Biomarker Changes

The Phase 3b study found higher rates of complete skin clearance and weight loss with the combination than with Taltz alone in adults with plaque psoriasis and obesity or overweight.

Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results

TLDR Eli Lilly stock gains 0.62% as new Phase 3b findings highlight treatment gains. Combined therapy changes 482 proteins versus 140 with Taltz alone by Week 36. Gene activity shifts span 467 genes with both drugs, versus 16 on Taltz alone. Taltz and Zepbound deliver improved skin clearance and weight loss at Week 36. Researchers [...]